Maintenance Therapy with Certolizumab Pegol for Crohn's Disease

Patients who had a response to open-label induction treatment with certolizumab pegol were randomly assigned to receive maintenance treatment with certolizumab pegol or placebo. At 26 weeks, more patients in the certolizumab group than in the placebo group had maintained their response (63% vs. 36%,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2007-07, Vol.357 (3), p.239-250
Hauptverfasser:	Schreiber, Stefan, Khaliq-Kareemi, Mani, Lawrance, Ian C, Thomsen, Ole Østergaard, Hanauer, Stephen B, McColm, Juliet, Bloomfield, Ralph, Sandborn, William J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Anti-Inflammatory Agents - therapeutic use Antibodies Antibodies, Antinuclear Antibodies, Monoclonal, Humanized Apoptosis Biological and medical sciences Bowel disease C-Reactive Protein - analysis Certolizumab Pegol Clinical trials Crohn Disease - classification Crohn Disease - drug therapy Crohn Disease - immunology Double-Blind Method Drug Therapy, Combination Female Follow-Up Studies Gastroenterology. Liver. Pancreas. Abdomen General aspects Humans Immunoglobulin Fab Fragments - adverse effects Immunoglobulin Fab Fragments - immunology Immunoglobulin Fab Fragments - therapeutic use Immunosuppressive Agents - therapeutic use Injections, Subcutaneous Male Medical sciences Middle Aged Other diseases. Semiology Pharmaceutical industry Polyethylene Glycols - adverse effects Polyethylene Glycols - therapeutic use Remission Induction Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients who had a response to open-label induction treatment with certolizumab pegol were randomly assigned to receive maintenance treatment with certolizumab pegol or placebo. At 26 weeks, more patients in the certolizumab group than in the placebo group had maintained their response (63% vs. 36%, P
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa062897